Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart clot study asks: when can you safely stop blood thinners?

NCT ID NCT07246005

Disease control Sponsor: Queen Mary University of London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study looks at people with a blood clot in the heart (left ventricular thrombus) who have been on blood thinners for at least 3 months. Half will stop their medication and half will continue, to see which approach is safer. The goal is to find the best treatment duration and to test whether a larger study is possible.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
rivaroxaban, apixaban, or warfarin (blood thinners)
What this could lead to
If successful, this could help doctors know the safest time to stop blood thinners in people with left ventricular thrombus, reducing bleeding risk while preventing strokes.
What could go wrong
This is a small pilot study, not a large definitive trial. It may not provide clear answers, and stopping blood thinners could increase the risk of stroke or new clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of LV thrombus less than 12 months ago * On Apixaban at the time of randomisation * Completed at least 3 months of anticoagulation treatment for LV thrombus * Persistent laminar/ mural thrombus or persistent LV dysfunction Exclusion Criteria: * Any clinical condition requiring long term anticoagulation treatment as per investigator's judgement. * SSE since LV thrombus diagnosis * Contraindication to continuing anticoagulation therapy * Non-ischaemic Cardiomyopathy * Age less than 18 years * Unable to consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Left ventricular thrombus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Left ventricular thrombus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • St Bartholomews Hospital

    London, EC1A4BE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.